Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation

ABCC8 and KCJN11 mutations cause the most severe diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are considered as secondline treatment in diazoxide-unresponsive cases. Current treatment protocols include the first-generation somatostatin analogue octreotide, al...

Descripción completa

Detalles Bibliográficos
Autores principales: Mooij, Christiaan F., Tacke, Carline E., van Albada, Mirjam E., Barthlen, Winfried, Bikker, Hennie, Mohnike, Klaus, Oomen, Matthijs W.N., van Trotsenburg, A.S. Paul, Zwaveling-Soonawala, Nitash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Pediatric Endocrinology 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749021/
https://www.ncbi.nlm.nih.gov/pubmed/33971706
http://dx.doi.org/10.6065/apem.2142010.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749021/
https://www.ncbi.nlm.nih.gov/pubmed/33971706
http://dx.doi.org/10.6065/apem.2142010.005

Ejemplares similares